Business
GeoVax Expands Gedeptin(R) Patent Portfolio
Allowed Patent Claims Cover the Synergistic Combination of Gedeptin(R) Therapy with Radiation As a Targeted Approach for Solid Tumors ATLANTA, GA - May 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company ...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Allowed Patent Claims Cover the Synergistic Combination of Gedeptin(R) Therapy with Radiation As a Targeted Approach for Solid Tumors","length":133,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - May 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against solid tumors and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance related to U.S. patent application 17/502,101 entitled "Enhanced Therapeutic Usage of a Purine Nucleoside Phosphorylase or Nucleoside Hydrolase Prodrug". The allowed claims further strengthen GeoVax's intellectual property position in the oncology space.","length":561,"tagName":"p"},{"type":"text","content":"The allowed claims describe a method for treating solid tumors - including glioblastoma, breast, prostate, head and neck, glioma, and lung cancers - through the direct intratumoral administration of an adenoviral vector encoding purine nucleoside phosphorylase (Ad/PNP), followed by local administration of the prodrug fludarabine phosphate (F-araAMP), and subsequent radiation therapy. This triple-combination strategy is designed to generate local, targeted cytotoxic activity within the tumor microenvironment while minimizing systemic toxicity.","length":548,"tagName":"p"},{"type":"text","content":"The allowed patent joins the growing Gedeptin intellectual property portfolio, which was exclusively licensed to GeoVax through a prior agreement with PNP Therapeutics, Inc. and the University of Alabama at Birmingham (UAB)/Southern Research. Under the agreement, GeoVax has assumed all licensing rights and IP prosecution responsibilities for the Gedeptin platform.","length":366,"tagName":"p"},{"type":"text","content":"David Dodd, Chairman and CEO of...